Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.
Keywords: Cardiovascular risk; diabetes mellitus; glucagon-like peptide-1 (GLP-1) receptor agonists; glucagon-like polypeptide; incretins; obesity; semaglutide.
© Touch Medical Media 2024.